Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
1.1
0.9
Journals
Hematology Reports
Special Issues
State of the Art Papers from 'The Society of Hematologic...
share announcement

State of the Art Papers from 'The Society of Hematologic Oncology Italy – SOHO ITALY'

A special issue of Hematology Reports (ISSN 2038-8330).

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 3379

Special Issue Editors

Dr. Giovanni Martinelli

E-Mail Website
Guest Editor
Department of Hematology and Sciences Oncology, Institute of Haematology “L. and A. Seràgnoli” S. Orsola, University of Bologna, Bologna, Italy
Interests: leukemias; lymphomas; acute leukemia; chronic myeloid leukemia
Special Issues, Collections and Topics in MDPI journals
Dr. Claudio Cerchione

E-Mail Website
Guest Editor
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, 47014 Meldola, Italy
Interests: acute lymphoblastic leukemia; acute myeloid leukemia; myelodysplastic syndromes; multiple myeloma and MGUS; non-Hodgkin and Hodgkin lymphoma
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Society of Hematologic Oncology Italy – SOHO ITALY, is bringing together leading SOHO experts and top international researchers in Acute Leukemias, MPDs and MDSs, Lymphomas, Multiple Myeloma and rare disaeses, aiming to consolidate the Italian Hematology-SOHO partnership.

The aim of the association is the integration of the clinical-scientific activities of IRST IRCCS and MD Anderson Cancer Center and the improvement of the clinical-therapeutic approach to patients with hematologic malignancies.The society SOHO ITALY is represented by the Presidents C. Cerchione, G. Martinelli (IRST IRCCS) and H. Kantarjian (MD Anderson Cancer Center),  and the other founders and members of the Scientific Board N. Daver, E. Jabbour, M. Konopleva (MD Anderson Cancer Center).

We establish this special issue aim to publish state of the art papers from society SOHO ITALY.

Dr. Giovanni Martinelli
Dr. Claudio Cerchione
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hematology Reports is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

11 pages, 912 KiB  
Review
How I Manage Chronic Lymphocytic Leukemia
by Patrice Nasnas, Claudio Cerchione, Gerardo Musuraca, Giovanni Martinelli and Alessandra Ferrajoli
Hematol. Rep. 2023, 15(3), 454-464; https://doi.org/10.3390/hematolrep15030047 - 01 Aug 2023
Cited by 3 | Viewed by 3018
Abstract
Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries. Its presentation can range from asymptomatic with the incidental finding of absolute lymphocytosis on a routine blood [...] Read more.
Chronic lymphocytic leukemia (CLL), is a hematologic malignancy characterized by the uncontrolled proliferation of mature B lymphocytes. CLL is the most prevalent leukemia in Western countries. Its presentation can range from asymptomatic with the incidental finding of absolute lymphocytosis on a routine blood test, to symptomatic disease requiring immediate intervention. Prognosis of the disease is defined by the presence or absence of specific mutations such as TP53, chromosomal abnormalities such as del(17p), a type of IGHV mutational status, and elevation of B2M and LDH. Treatment of CLL in the United States and Europe has evolved over the recent years thanks to the development of targeted therapies. The standard of care has shifted from traditional chemoimmunotherapy approaches to targeted therapies including Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitors, administered either as monotherapy or in combination with CD20 monoclonal antibodies. Several clinical trials have also recently evaluated combinations of BTKi and venetoclax and showed the combination to be well tolerated and able to induce deep remissions. Targeted therapies have a good safety profile overall; however, they also have unique toxicities that are important to recognize. Diarrhea, fatigue, arthralgia, infections, cytopenias, bleeding, and cardiovascular toxicities (including atrial fibrillation, ventricular arrhythmias, and hypertension) are the adverse events (AEs) commonly associated with BTKis. Initiation of therapy with venetoclax requires close monitoring because of the risk for tumor lysis syndrome associated with this agent, particularly in patients with a high disease burden. Development of newer target therapies is ongoing and the therapeutic landscape in CLL is expanding rapidly. Full article
(This article belongs to the Special Issue State of the Art Papers from 'The Society of Hematologic Oncology Italy – SOHO ITALY')
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop